person · Reporting owner

Atkinson Edward Morrow III

Disclosed activity across 2 companies

Tapewire entity: 14916
SEC CIK: 0001914164

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875	EVP, Chief Technical Ops. Off.	February 24, 2026	February 26, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

VERTEX PHARMACEUTICALS INC / MA

Report date February 24, 2026 · Filed February 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,432	Ending reported balance After 2026-02-25 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-02-24 · Tax withholding · Disposed 1,627 · Balance 19,100 Row 2 · 2026-02-25 · Sale · Disposed 668 · Balance 18,432 F1: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

89bio, Inc.

Report date October 30, 2025 · Filed October 30, 2025

Section 16 reporting ended · disclosed 2025-10-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2032-02-17	Direct	Reported balance After 2025-10-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-10-30 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.70 · Expires 2033-02-09	Direct	Reported balance After 2025-10-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-10-30 · Disposition to issuer · Disposed 27,400 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.98 · Expires 2034-02-01	Direct	Reported balance After 2025-10-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-10-30 · Disposition to issuer · Disposed 45,150 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.60 · Expires 2035-02-01	Direct	Reported balance After 2025-10-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-10-30 · Disposition to issuer · Disposed 56,400 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]

F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4]

F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]

F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 25, 2026 Filed Feb 26, 2026 23:00 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	668	$486.35	$324,881.80	Disclosure SEC source: 0000875320-26-000106 · wk-form4_1772146808.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,432 F1 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025. Read SEC document
February 24, 2026 Filed Feb 26, 2026 23:00 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Tax withholdingCommon Stock	1,627	$485.11	$789,273.97	Disclosure SEC source: 0000875320-26-000106 · wk-form4_1772146808.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,100 Read SEC document
February 18, 2026 Filed Feb 19, 2026 21:06 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	817	$473.68	$386,996.56	Disclosure SEC source: 0000875320-26-000082 · wk-form4_1771535181.xml · nonDerivative · entry 4 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,727 F2 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025. Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:06 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	2,031	$489.46	$994,093.26	Disclosure SEC source: 0000875320-26-000082 · wk-form4_1771535181.xml · nonDerivative · entry 3 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,544 F2 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025. Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:06 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Tax withholdingCommon Stock	1,530	$483.75	$740,137.50	Disclosure SEC source: 0000875320-26-000082 · wk-form4_1771535181.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,575 Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:06 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	4,962	$0.00	$0.00	Disclosure SEC source: 0000875320-26-000082 · wk-form4_1771535181.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,105 F1 · shares: Restricted stock unit award that vests in installments beginning on February 20, 2027. Read SEC document
February 13, 2026 Filed Feb 18, 2026 21:19 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Tax withholdingCommon Stock	1,903	$487.76	$928,207.28	Disclosure SEC source: 0000875320-26-000060 · wk-form4_1771449589.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,143 Read SEC document
February 11, 2026 Filed Feb 12, 2026 21:50 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,751	$460.43	$806,212.93	Disclosure SEC source: 0000875320-26-000038 · wk-form4_1770933003.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,046 F1 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025. Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:50 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Tax withholdingCommon Stock	872	$468.41	$408,453.52	Disclosure SEC source: 0000875320-26-000038 · wk-form4_1770933003.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,797 Read SEC document
January 22, 2026 Filed Jan 26, 2026 21:17 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	3,883	$0.00	$0.00	Disclosure SEC source: 0000875320-26-000012 · wk-form4_1769462267.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,669 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026. Read SEC document
January 22, 2026 Filed Jan 26, 2026 21:17 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	3,934	$0.00	$0.00	Disclosure SEC source: 0000875320-26-000012 · wk-form4_1769462267.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,786 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026. Read SEC document
November 17, 2025 Filed Nov 19, 2025 21:06 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	2,500	$434.58	$1,086,450.00	Disclosure SEC source: 0000875320-25-000236 · wk-form4_1763586372.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,852 F1 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025. Read SEC document
October 30, 2025 Filed Oct 30, 2025 20:19 UTC	89bio, Inc. ETNB · Entity 73682	Disposition to issuerStock Option (Right to Buy) · Derivative	56,400	$0.00 Strike: $9.60	$0.00	Disclosure SEC source: 0001193125-25-259047 · ownership.xml · derivative · entry 4 Atkinson Edward Morrow III · CIK 0001914164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,400 shares Expires 2035-02-01 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document
October 30, 2025 Filed Oct 30, 2025 20:19 UTC	89bio, Inc. ETNB · Entity 73682	Disposition to issuerStock Option (Right to Buy) · Derivative	45,150	$0.00 Strike: $9.98	$0.00	Disclosure SEC source: 0001193125-25-259047 · ownership.xml · derivative · entry 3 Atkinson Edward Morrow III · CIK 0001914164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,150 shares Expires 2034-02-01 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document
October 30, 2025 Filed Oct 30, 2025 20:19 UTC	89bio, Inc. ETNB · Entity 73682	Disposition to issuerStock Option (Right to Buy) · Derivative	27,400	$0.00 Strike: $14.70	$0.00	Disclosure SEC source: 0001193125-25-259047 · ownership.xml · derivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,400 shares Expires 2033-02-09 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document
October 30, 2025 Filed Oct 30, 2025 20:19 UTC	89bio, Inc. ETNB · Entity 73682	Disposition to issuerStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $4.44	$0.00	Disclosure SEC source: 0001193125-25-259047 · ownership.xml · derivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2032-02-17 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document
February 27, 2025 Filed Feb 28, 2025 21:36 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	2,650	$475.34	$1,259,651.00	Disclosure SEC source: 0000875320-25-000127 · wk-form4_1740778570.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,352 F1 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 02/22/2024. Read SEC document
February 26, 2025 Filed Feb 28, 2025 21:36 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Tax withholdingCommon Stock	2,482	$479.61	$1,190,392.02	Disclosure SEC source: 0000875320-25-000127 · wk-form4_1740778570.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,002 Read SEC document
February 25, 2025 Filed Feb 26, 2025 21:09 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,767	$480.95	$849,838.65	Disclosure SEC source: 0000875320-25-000107 · wk-form4_1740604171.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,484 F1 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 02/22/2024. Read SEC document
February 24, 2025 Filed Feb 26, 2025 21:09 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Tax withholdingCommon Stock	1,656	$483.28	$800,311.68	Disclosure SEC source: 0000875320-25-000107 · wk-form4_1740604171.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,251 Read SEC document
February 14, 2025 Filed Feb 19, 2025 21:26 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Tax withholdingCommon Stock	1,529	$463.46	$708,630.34	Disclosure SEC source: 0000875320-25-000083 · wk-form4_1740000364.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,907 Read SEC document
February 12, 2025 Filed Feb 14, 2025 21:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	6,211	$0.00	$0.00	Disclosure SEC source: 0000875320-25-000061 · wk-form4_1739567303.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,436 F1 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2026. Read SEC document
February 11, 2025 Filed Feb 12, 2025 21:29 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,747	$459.83	$803,323.01	Disclosure SEC source: 0000875320-25-000037 · wk-form4_1739395783.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,225 F1 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 02/22/2024. Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:29 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Tax withholdingCommon Stock	876	$467.98	$409,950.48	Disclosure SEC source: 0000875320-25-000037 · wk-form4_1739395783.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,972 Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:21 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	4,744	$0.00	$0.00	Disclosure SEC source: 0000875320-25-000011 · wk-form4_1738876909.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,848 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025. Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:21 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	5,132	$0.00	$0.00	Disclosure SEC source: 0000875320-25-000011 · wk-form4_1738876909.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,104 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025. Read SEC document
February 03, 2025 Filed Feb 5, 2025 16:01 UTC	89bio, Inc. ETNB · Entity 73682	GrantStock Option (Right to Buy) · Derivative	56,400	$0.00 Strike: $9.60	$0.00	Disclosure SEC source: 0000950170-25-014437 · ownership.xml · derivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,400 Underlying: Common Stock · 56,400 shares Expires 2035-02-03 F1 · derivative.exercise_date: This option represents a right to purchase a total of 56,400 shares of the Issuer's Common Stock, which will vest in full on February 1, 2026, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document
June 12, 2024 Filed Jun 13, 2024 20:09 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	7,288	$478.00	$3,483,664.00	Disclosure SEC source: 0000875320-24-000174 · wk-form4_1718309345.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,972 F1 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 02/22/2024. Read SEC document
June 11, 2024 Filed Jun 13, 2024 20:09 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Tax withholdingCommon Stock	6,824	$481.96	$3,288,895.04	Disclosure SEC source: 0000875320-24-000174 · wk-form4_1718309345.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,260 Read SEC document
May 14, 2024 Filed May 16, 2024 20:12 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	14,112	$0.00	$0.00	Disclosure SEC source: 0000875320-24-000144 · wk-form4_1715890307.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,084 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 05/19/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 05/14/2024 and the shares will vest on 06/10/2024. Read SEC document
February 26, 2024 Filed Feb 27, 2024 21:44 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	883	$425.70	$375,893.10	Disclosure SEC source: 0000875320-24-000101 · wk-form4_1709070192.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,972 F1 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 8/22/2023. Read SEC document
February 23, 2024 Filed Feb 27, 2024 21:44 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Tax withholdingCommon Stock	1,654	$431.79	$714,180.66	Disclosure SEC source: 0000875320-24-000101 · wk-form4_1709070192.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,855 Read SEC document
February 21, 2024 Filed Feb 23, 2024 21:16 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,201	$421.77	$506,545.77	Disclosure SEC source: 0000875320-24-000089 · wk-form4_1708722946.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,509 F1 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 8/22/2023. Read SEC document
February 20, 2024 Filed Feb 21, 2024 21:23 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	801	$420.79	$337,052.79	Disclosure SEC source: 0000875320-24-000070 · wk-form4_1708550607.xml · nonDerivative · entry 3 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,710 F1 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 8/22/2023. Read SEC document
February 20, 2024 Filed Feb 21, 2024 21:23 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Tax withholdingCommon Stock	1,125	$420.58	$473,152.50	Disclosure SEC source: 0000875320-24-000070 · wk-form4_1708550607.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,511 Read SEC document
February 16, 2024 Filed Feb 21, 2024 21:23 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Tax withholdingCommon Stock	1,501	$424.01	$636,439.01	Disclosure SEC source: 0000875320-24-000070 · wk-form4_1708550607.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,636 Read SEC document
February 12, 2024 Filed Feb 13, 2024 21:54 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	913	$420.24	$383,679.12	Disclosure SEC source: 0000875320-24-000045 · wk-form4_1707861239.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,137 F1 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 8/22/2023. Read SEC document
February 09, 2024 Filed Feb 13, 2024 21:54 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Tax withholdingCommon Stock	832	$422.74	$351,719.68	Disclosure SEC source: 0000875320-24-000045 · wk-form4_1707861239.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,050 Read SEC document
February 07, 2024 Filed Feb 8, 2024 21:24 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	4,743	$0.00	$0.00	Disclosure SEC source: 0000875320-24-000020 · wk-form4_1707427484.xml · nonDerivative · entry 3 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,882 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2025. Read SEC document
February 06, 2024 Filed Feb 8, 2024 21:24 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	3,934	$0.00	$0.00	Disclosure SEC source: 0000875320-24-000020 · wk-form4_1707427484.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,139 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024. Read SEC document
February 06, 2024 Filed Feb 8, 2024 21:24 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	2,326	$0.00	$0.00	Disclosure SEC source: 0000875320-24-000020 · wk-form4_1707427484.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,205 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024. Read SEC document
February 01, 2024 Filed Feb 5, 2024 20:15 UTC	89bio, Inc. ETNB · Entity 73682	GrantStock Option (Right to Buy) · Derivative	45,150	$0.00 Strike: $9.98	$0.00	Disclosure SEC source: 0000950170-24-011474 · ownership.xml · derivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,150 Underlying: Common Stock · 45,150 shares Expires 2034-02-01 F1 · derivative.exercise_date: This option represents a right to purchase a total of 45,150 shares of the Issuer's Common Stock, which will vest in full on February 1, 2025, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document
June 01, 2023 Filed Jun 5, 2023 17:03 UTC	89bio, Inc. ETNB · Entity 73682	Exercise / conversionStock Option (Right to Buy) · Derivative	6,250	$0.00 Strike: $2.61	$0.00	Disclosure SEC source: 0000950170-23-026422 · ownership.xml · derivative · entry 3 Atkinson Edward Morrow III · CIK 0001914164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2032-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option represents a right to purchase a total of 6,250 shares of the Issuer's Common Stock, which vested in full on May 16, 2023. Read SEC document
June 01, 2023 Filed Jun 5, 2023 17:03 UTC	89bio, Inc. ETNB · Entity 73682	SaleCommon Stock	6,250	$17.91	$111,937.50	Disclosure SEC source: 0000950170-23-026422 · ownership.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on January 30, 2023 in multiple trades at prices ranging from $17.53 to $18.18. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 01, 2023 Filed Jun 5, 2023 17:03 UTC	89bio, Inc. ETNB · Entity 73682	Exercise / conversionCommon Stock	6,250	$2.61	$16,312.50	Disclosure SEC source: 0000950170-23-026422 · ownership.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2023 Filed Mar 3, 2023 17:18 UTC	89bio, Inc. ETNB · Entity 73682	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $4.44	$0.00	Disclosure SEC source: 0000899243-23-007032 · doc4.xml · derivative · entry 3 Atkinson Edward Morrow III · CIK 0001914164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2032-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option represents a right to purchase a total of 30,000 shares of the Issuer's Common Stock, which vests in equal installments on February 17, 2023, February 17, 2024 and February 17, 2025, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
March 01, 2023 Filed Mar 3, 2023 17:18 UTC	89bio, Inc. ETNB · Entity 73682	SaleCommon Stock	10,000	$13.60	$136,000.00	Disclosure SEC source: 0000899243-23-007032 · doc4.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $13.49 to $14.83. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 01, 2023 Filed Mar 3, 2023 17:18 UTC	89bio, Inc. ETNB · Entity 73682	Exercise / conversionCommon Stock	10,000	$4.44	$44,400.00	Disclosure SEC source: 0000899243-23-007032 · doc4.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 09, 2023 Filed Feb 13, 2023 17:33 UTC	89bio, Inc. ETNB · Entity 73682	GrantStock Option (Right to Buy) · Derivative	27,400	$0.00 Strike: $14.70	$0.00	Disclosure SEC source: 0000899243-23-004796 · doc4.xml · derivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,400 Underlying: Common Stock · 27,400 shares Expires 2033-02-09 F1 · derivative.exercise_date: This option represents a right to purchase a total of 27,400 shares of the Issuer's Common Stock, which will vest in full on February 9, 2024, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document
May 25, 2022 Filed May 27, 2022 16:15 UTC	89bio, Inc. ETNB · Entity 73682	GrantStock Option (Right to Buy) · Derivative	6,250	$0.00 Strike: $2.61	$0.00	Disclosure SEC source: 0000899243-22-019926 · doc4.xml · derivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2032-05-25 F1 · derivative.exercise_date: This option represents a right to purchase a total of 6,250 shares of the Issuer's Common Stock, which will vest in full on May 16, 2023, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.